This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $87, moving -0.55% from the previous trading session.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Time to Buy CVS or Oak Street Health Stock on Potential Acquisition?
by Shaun Pruitt
News of CVS Health (CVS) potentially acquiring Oak Street Health (OHS) for $10 billion broke this week and highlighted what could be another lucrative acquisition in 2023.
5 Retail Stocks That Could Rally on Lower Inflation
by Shaun Pruitt
Consumer data showing signs of deflation on a month-to-month basis is promising for the broader stock market. This is especially significant for the Retail and Wholesale sector and a stronger consumer could lead to more upside in these five stocks.
The Zacks Analyst Blog Highlights JPMorgan Chase, Chevron, Salesforce, CVS Health and FedEx
by Zacks Equity Research
JPMorgan Chase, Chevron, Salesforce, CVS Health and FedEx are included in this Analyst Blog.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $89.75 in the latest trading session, marking a -0.99% move from the prior day.
Top Research Reports for JPMorgan Chase, Chevron & Salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Chevron Corporation (CVX) and Salesforce, Inc. (CRM).
Why CVS Health (CVS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
World Bank Sees Slow Growth in 2023
by Mark Vickery
The World Bank has slashed its 2023 growth projection from to +1.7% from +3% it just six short months ago.
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $91.98, moving -1% from the previous trading session.
CVS Health (CVS) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $93.45, moving +0.74% from the previous trading session.
CVS Health (CVS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed at $93.02 in the latest trading session, marking a -0.58% move from the prior day.
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $95, marking a -0.05% move from the previous day.
CVS Health (CVS) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $95.05, moving -0.42% from the previous trading session.
The Zacks Analyst Blog Highlights Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte
by Zacks Equity Research
Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte are included in this Analyst Blog.
Top Research Reports for Verizon, Honeywell & CVS Health
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks,including Verizon Communications Inc. (VZ), Honeywell International Inc. (HON) and CVS Health Corporation (CVS).
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Foot Locker (FL) Stock Up 8.7% on Q3 Earnings and Sales Beat
by Zacks Equity Research
Foot Locker (FL) posts better-than-expected earnings for third-quarter fiscal 2022. FL's FLX membership program and omnichannel capabilities appear encouraging.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Company News for Nov 3, 2022
by Zacks Equity Research
Companies In The News Are: CVS, HUM, ETR, NVO.